Patent Law in Biotechnology, Chemicals & Pharmaceuticals
β Scribed by Harold C. Wegner (auth.)
- Publisher
- Palgrave Macmillan UK
- Year
- 1992
- Tongue
- English
- Leaves
- 524
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
β¦ Synopsis
A practical guide to patent prosecution and strategy in the US with particular reference to invention in chemicals and biotechnology. The presentation is focused on case law in the US and deals with specific cases. A section is devoted to international patent protection.
β¦ Table of Contents
Front Matter....Pages N1-xviii
Overview....Pages 1-6
Trade Secrets....Pages 7-27
Patent Overview....Pages 29-38
The Paris Convention....Pages 39-43
Other Treaties....Pages 44-45
Patent Procurement Strategies....Pages 46-52
Drafting the Patent Application....Pages 53-62
Patent-Eligible Subject Matter....Pages 64-69
Novelty (Anticipation)....Pages 70-87
First Inventor System....Pages 89-93
Priority Based upon an Earlier Patent Application....Pages 94-99
Priority upon Proof of Early Date of Invention....Pages 100-106
Interference Procedures....Pages 107-114
Interference Strategies....Pages 115-118
Obviousness....Pages 119-155
Homologs, Isomers and Analogs....Pages 156-161
Proving a Difference in Properties....Pages 162-176
Method of Use Claim Obviousness Issues....Pages 177-189
Method of Making Obviousness Issues....Pages 190-203
Product-By-Process Claims....Pages 204-207
Purity and Activity Level Limitations....Pages 208-209
Jepson and Other Prior Art βAdmissionsβ....Pages 210-213
Claims and Their Interpretation....Pages 216-222
Claim Structure....Pages 223-232
βMeansβ Limitations....Pages 233-235
Determining the Literal Scope of the Claim....Pages 236-252
Infringing Acts Under Varying Statutory Categories....Pages 253-294
Infringement Determination....Pages 295-304
The Doctrine of Equivalents....Pages 305-315
File Wrapper (Prosecution History) Estoppel....Pages 316-324
The Reverse Doctrine of Equivalents....Pages 325-331
Disclosure Requirements....Pages 332-337
The Written Description Requirement....Pages 338-348
Enablement, βHow to Makeβ....Pages 349-355
Enablement, βHow to Useβ....Pages 356-371
The βBest Mode Contemplated * * *β....Pages 372-391
Biotechnology Deposits....Pages 392-422
Duty of Disclosure....Pages 423-438
Double Patenting....Pages 439-444
Restriction Practice....Pages 445-447
Election of Species....Pages 448-449
Markush-Election Interface....Pages 450-470
International Unity Standards....Pages 471-474
International Practice Differences....Pages 475-481
Back Matter....Pages 483-514
β¦ Subjects
Commercial Law; Biomedicine general; Chemistry/Food Science, general; Biotechnology; Biomedical Engineering/Biotechnology
π SIMILAR VOLUMES
European law has been faced with increasingly complex issues emerging from rapid developments in pharmaceutical medicine and biotechnology. A team of distinguished European legal practitioners and academics reassess the impact of European law on health care and pharmaceutical law. The essays are gro
European law has been faced with increasingly complex issues emerging from rapid developments in pharmaceutical medicine and biotechnology. A team of distinguished European legal practitioners and academics reassess the impact of European law on health care and pharmaceutical law. The essays are gro
This book contains the English language texts of all GMPs (regulations, guidelines, codes, and practices) implemented by national and international regulatory authorities that govern the manufacture and testing of biotechnology-derived products, active pharmaceutical ingredients, and pharmaceuticals